<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>255781</rcn>
  <id>101123436</id>
  <acronym>MiTE</acronym>
  <teaser>Immunotherapy holds great promise for the curative treatment of millions of cancer patients, with a market size of over 100 billion USD today, which is expected to at least double in the next decade. Cancer immunotherapies are designed either to promote anti-tumor immune...</teaser>
  <objective>Immunotherapy holds great promise for the curative treatment of millions of cancer patients, with a market size of over 100 billion USD today, which is expected to at least double in the next decade. Cancer immunotherapies are designed either to promote anti-tumor immune activity in the tumor microenvironment (TME), via molecules such as cytokines and antibodies, or to inhibit negative T cell signals induced by cancer and antigen-presenting cells (APCs) in the TME, an approach known as immune checkpoint blockade (ICB). Yet current immunotherapies have shown significant clinical success only against a limited number of cancers, for two major reasons: insufficient anti-tumor immune activation or severe side effects and toxicity as a result of nonspecific immune activation. We propose to overcome these two challenges through the development of a novel class of molecules capable of simultaneously modulating the myeloid and lymphoid immune cell compartments in the TME and generating a highly specific and extremely potent antitumor immune response. In this PoC grant, we seek to validate the ability to construct such dual-modulatory agents, which will provide us with the proof-of-concept for these technologies.</objective>
  <title>Developing the next generation of cis-targeting macrophage-T cell cancer immunotherapies</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2023-06-01</startDate>
  <endDate>2025-05-31</endDate>
  <ecSignatureDate>2023-05-23</ecSignatureDate>
  <duration>24</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101123436</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate>2023-09-19 18:32:11</contentCreationDate>
  <contentUpdateDate>2023-09-19 18:32:08</contentUpdateDate>
  <lastUpdateDate>2025-10-27 12:14:18</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>456019</rcn>
        <id>456019-next-generation-cancer-immunotherapy</id>
        <title>Next generation cancer immunotherapy</title>
        <contentUpdateDate>2025-05-05 14:18:46</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55832</rcn>
        <title>ERC-2023-POC</title>
        <identifier>ERC-2023-POC</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55832</rcn>
        <title>ERC-2023-POC</title>
        <identifier>ERC-2023-POC</identifier>
      </call>
      <organization netEcContribution="150000" totalCost="0" source="corda" order="1" ecContribution="150000" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1906414</rcn>
        <id>999979306</id>
        <vatNumber>IL520016858</vatNumber>
        <legalName>WEIZMANN INSTITUTE OF SCIENCE</legalName>
        <shortName>WEIZMANN</shortName>
        <address>
          <street>HERZL STREET 234</street>
          <city>Rehovot</city>
          <postalCode>7610001</postalCode>
          <country>IL</country>
          <postBox>26</postBox>
          <url>http://www.weizmann.ac.il</url>
          <geolocation>31.8952532,34.8105616</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>707186</rcn>
        <id>HORIZON_ERC-2023-POC</id>
        <code>ERC-2023-POC</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1362551</rcn>
        <id>101123436_225789_PUBLIHORIZON</id>
        <title>ZEB2 is a master switch controlling the tumor-associated macrophage program</title>
        <details>
          <authors>Fadi Sheban, Truong San Phan, Ken Xie, Florian Ingelfinger, Chamutal Gur, Yuval Shapir Itai, Ronnie Blecher-Gonen, Chunsong Yu, Roberto Avellino, Paulina Chalan, Kiara Freitag, Ido Yofe, Vladimir Yutkin, Pierre Boyeau, Can Ergen, Justin Hong, Kfir Mazuz, Yuxiao Liu, Kangming Chen, Rony Dahan, Marcin Kortylewski, Nir Yosef, Assaf Weiner, Ido Amit</authors>
          <journalNumber>43</journalNumber>
          <journalTitle>Cancer Cell</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2025</publishedYear>
          <publisher>Elsevier BV</publisher>
        </details>
        <identifiers>
          <issn>1535-6108</issn>
          <doi>10.1016/J.CCELL.2025.03.021</doi>
        </identifiers>
        <sourceUpdateDate>2025-09-16 13:35:51</sourceUpdateDate>
        <contentUpdateDate>2025-09-22 10:59:10</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode>/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1374948</rcn>
        <id>101123436_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - MiTE (Developing the next generation of cis-targeting macrophage-T cell cancer immunotherapies)</title>
        <description>periodic</description>
        <teaser>Cancer remains one of the leading causes of death, affecting millions of people every year. Immunotherapy - a treatment that activates the body’s own immune system to fight cancer - has already transformed the way some cancers are treated. The global market for immunotherapy...</teaser>
        <sourceUpdateDate>2025-10-20 17:42:54</sourceUpdateDate>
        <contentUpdateDate>2025-10-27 12:14:15</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/643</code>
        <title>immunotherapy</title>
        <displayCode>/medical and health sciences/basic medicine/immunology/immunotherapy</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode>/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>